Current Filters

Showing 3431 - 3439 results of 3439

Patient Self-registration Kiosks (Last Updated: Aug 11, 2022)

This is a new CADTH project. Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of...
Project Status:
In Progress

Peer Support Programs for Youth Mental Health (Last Updated: Aug 12, 2022)

Peer support is the relationship between a peer client and a peer support worker who share lived experience. Through face-to-face or virtual interactions, the peer support worker supports the peer...
Project Line:
Health Technology Review
Project Status:
In Progress

cenegermin (Oxervate) (Last Updated: Jul 12, 2022)

Project Line:
Reimbursement Review
Project Status:
Active
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Oxervate
Manufacturer:
Dompé Farmaceutici S.p.A
Submission Type:
Initial
Indications:

For the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.

Real-World Evidence and Real-World Data Guidance (Last Updated: Jul 27, 2022)

There is increasing interest in the use of real-world data (RWD) to generate real-world evidence (RWE) to complement evidence from randomized clinical trials for the purpose of decision-making. As a...
Project Line:
Methods and Guidelines

nusinersen (Spinraza) (Last Updated: Aug 11, 2022)

Project Line:
Reimbursement Review
Project Status:
Active
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Spinraza
Manufacturer:
Biogen Canada Inc.
Submission Type:
Reassessment
Indications:

Spinraza (nusinersen) is indicated for the treatment of 5q Spinal Muscular Atrophy (SMA).

pitolisant hydrochloride (Wakix) (Last Updated: Aug 11, 2022)

Project Line:
Reimbursement Review
Project Status:
Active
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Wakix
Manufacturer:
Paladin Labs Inc.
Submission Type:
Initial
Indications:

Wakix (pitolisant hydrochloride tablets) is indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy.

edaravone (TBC) (Last Updated: Aug 11, 2022)

Project Line:
Reimbursement Review
Project Status:
Active
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
TBC
Manufacturer:
Mitsubishi Tanabe Pharma Canada, Inc.
Submission Type:
Initial
Indications:

For the treatment of amyotrophic lateral sclerosis (ALS).

mepolizumab (Nucala) (Last Updated: Aug 11, 2022)

Project Line:
Reimbursement Review
Project Status:
Active
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Nucala
Manufacturer:
GlaxoSmithKline Inc.
Submission Type:
Initial
Indications:

Nucala is indicated as add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by intranasal corticosteroids alone.

Download results as CSV